On February 5, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2026 that ended December 31, 2025 and provided a business update. The company recently launched REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS). Sales of the drug are off to an encouraging start, with over 100 prescriptions filled since the end of November. REDEMPLO also recently received approval by Health Canada and from the Chinese National Medical Products Administration. Arrowhead recently initiated a Phase 1/2 clinical trial of ARO-DIMER-PA, which is a dual functional RNAi therapeutic designed to silence the expression of the PCSK9 and APOC3 genes. We anticipate interim data from that study in the second half of 2026.
